News >

Levy Lends Insight on Pivotal NSCLC Trials

Caroline Seymour
Published: Thursday, Mar 01, 2018

Dr. Benjamin P. Levy

Benjamin P. Levy, MD
Researchers are looking to further improve outcomes in non–small cell lung cancer (NSCLC) through a novel regimen of immunotherapy, angiogenesis inhibition, and chemotherapy—a synergistic combination that Benjamin P. Levy, MD, says would be exciting to have in the landscape.

Levy, assistant professor of oncology, clinical director, Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospital, expanded on these strategies and highlighted other trials that continue to shape the treatment landscape for patients with lung cancer.

OncLive: Can you discuss the data we have with frontline pembrolizumab and chemotherapy from the KEYNOTE-189 trial?

Levy: What we know right now is that single-agent pembrolizumab is the standard of care for patients with a PD-L1 score greater than 50% in advanced-staged patients. However, there are new data emerging from KEYNOTE-189, which is a randomized phase III trial comparing carboplatin/pemetrexed versus carboplatin/pemetrexed with the addition of pembrolizumab.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication